Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS
Dec 03, 2024
Contract Type
agreement
San DiegoBiotechnologyHealth CareMedicalTherapeuticsresearch
Description
Aptose Biosciences Inc. has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the clinical development of tuspetinib, an inhibitor of key signaling kinases involved in myeloid malignancies, in the NCI Cancer Therapy Evaluation Program (CTEP) sponsored myeloMATCH trials for the treatment of molecularly defined acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) populations.
Company Information
Company
Aptose Biosciences
Location
12770 High Bluff Dr
San Diego, California, United States
About
Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies.
San DiegoBiotechnologyHealth CareMedicalTherapeuticsresearch